ROCKVILLE, Md.--Celera Genomics here said it has entered a five-year deal to provide a subscription to its database products and early access to new genomic information to Novartis Pharma. Through the subscription, which includes access to associated bioinformatics tools for viewing, browsing, and analyzing genomics information, Novartis will gain access to Celera's human gene index, its Drosophila genome database, and its human genome database. Celera has also licensed its database products to Pharmacia and Upjohn and Amgen. Terms of the deals have not been announced.
Celera Cuts Third Database Deal With Novartis Pharma
Apr 23, 1999